{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:51Z","timestamp":1782409671726,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10147-026-03046-7","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:24:13Z","timestamp":1779211453000},"page":"1316-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of early tumor shrinkage in metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based combination therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Naoki","family":"Matsuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2815","authenticated-orcid":false,"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"3046_CR1","unstructured":"Cancer of the Kidney and Renal Pelvis - Cancer Stat Facts In: SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed 19 Sept 2025"},{"key":"3046_CR2","unstructured":"Cancer Today https:\/\/gco.iarc.who.int\/today\/. Accessed 19 Sept 2025"},{"key":"3046_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F et al (2022) Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 82:529\u2013542. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.019","journal-title":"Eur Urol"},{"key":"3046_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC et al (2020) Epidemiology of renal cell carcinoma. World J Oncol 11:79\u201387. https:\/\/doi.org\/10.14740\/wjon1279","journal-title":"World J Oncol"},{"key":"3046_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865\u2013875. https:\/\/doi.org\/10.1056\/NEJM199609193351207","journal-title":"N Engl J Med"},{"key":"3046_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"3046_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047","journal-title":"N Engl J Med"},{"key":"3046_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"3046_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"N Engl J Med"},{"key":"3046_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"3046_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11523-015-0385-6","volume":"11","author":"H Miyake","year":"2016","unstructured":"Miyake H, Miyazaki A, Imai S et al (2016) Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan. Targ Oncol 11:175\u2013182. https:\/\/doi.org\/10.1007\/s11523-015-0385-6","journal-title":"Targ Oncol"},{"key":"3046_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","volume":"6","author":"V Gr\u00fcnwald","year":"2023","unstructured":"Gr\u00fcnwald V, Powles T, Kopyltsov E et al (2023) Survival by depth of response and efficacy by international metastatic renal cell carcinoma database consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study. Eur Urol Oncol 6:437\u2013446. https:\/\/doi.org\/10.1016\/j.euo.2023.01.010","journal-title":"Eur Urol Oncol"},{"key":"3046_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/jjco\/hyab142","volume":"51","author":"H Ishihara","year":"2021","unstructured":"Ishihara H, Kondo T, Nakamura K et al (2021) Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Jpn J Clin Oncol 51:1751\u20131756. https:\/\/doi.org\/10.1093\/jjco\/hyab142","journal-title":"Jpn J Clin Oncol"},{"key":"3046_CR14","doi-asserted-by":"publisher","unstructured":"Mita Y, Teishima J, Hara T et al (2025) Prognostic impact of the maximal evaluable lesion size in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab combination therapy. Int J Urol iju 70065. https:\/\/doi.org\/10.1111\/iju.70065","DOI":"10.1111\/iju.70065"},{"key":"3046_CR15","doi-asserted-by":"publisher","first-page":"682449","DOI":"10.3389\/fonc.2021.682449","volume":"11","author":"M Stellato","year":"2021","unstructured":"Stellato M, Santini D, Verzoni E et al (2021) Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology: a real-world study on behalf of Meet-URO Group (MeetUro-7b). Front Oncol 11:682449. https:\/\/doi.org\/10.3389\/fonc.2021.682449","journal-title":"Front Oncol"},{"key":"3046_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1464-410X.2012.11518.x","volume":"110","author":"R Iacovelli","year":"2012","unstructured":"Iacovelli R, Lanoy E, Albiges L, Escudier B (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747\u20131753. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11518.x","journal-title":"BJU Int"},{"key":"3046_CR17","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1038\/bjc.2013.662","volume":"109","author":"C Seidel","year":"2013","unstructured":"Seidel C, Busch J, Weikert S et al (2013) Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer 109:2998\u20133004. https:\/\/doi.org\/10.1038\/bjc.2013.662","journal-title":"Br J Cancer"},{"key":"3046_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1634\/theoncologist.2013-0391","volume":"19","author":"KM Krajewski","year":"2014","unstructured":"Krajewski KM, Franchetti Y, Nishino M et al (2014) 10% tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19:507\u2013514. https:\/\/doi.org\/10.1634\/theoncologist.2013-0391","journal-title":"Oncologist"},{"key":"3046_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2014.12.036","volume":"67","author":"V Gr\u00fcnwald","year":"2015","unstructured":"Gr\u00fcnwald V, McKay RR, Krajewski KM et al (2015) Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67:952\u2013958. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.036","journal-title":"Eur Urol"},{"key":"3046_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jjco\/hyw024","volume":"46","author":"H Ishihara","year":"2016","unstructured":"Ishihara H, Kondo T, Omae K et al (2016) The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 46:568\u2013574. https:\/\/doi.org\/10.1093\/jjco\/hyw024","journal-title":"Jpn J Clin Oncol"},{"key":"3046_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.eururo.2016.05.010","volume":"70","author":"V Gr\u00fcnwald","year":"2016","unstructured":"Gr\u00fcnwald V, Lin X, Kalanovic D, Simantov R (2016) Early tumour shrinkage: a tool for the detection of early clinical activity in metastatic renal cell carcinoma. Eur Urol 70:1006\u20131015. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.010","journal-title":"Eur Urol"},{"key":"3046_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10147-016-1032-7","volume":"22","author":"H Ishihara","year":"2017","unstructured":"Ishihara H, Yagisawa T, Kondo T et al (2017) Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. Int J Clin Oncol 22:126\u2013135. https:\/\/doi.org\/10.1007\/s10147-016-1032-7","journal-title":"Int J Clin Oncol"},{"key":"3046_CR23","doi-asserted-by":"publisher","unstructured":"Hara T, Ueki H, Okamura Y et al (2025) Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer. Urol Oncol Semin Original Investig 43:63.e19-63.e27 https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.015","DOI":"10.1016\/j.urolonc.2024.10.015"},{"key":"3046_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2024.03.015","volume":"86","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Choueiri TK, Hutson T et al (2024) Characterization of responses to lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma at the final prespecified survival analysis of the phase 3 CLEAR study. Eur Urol 86:4\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.015","journal-title":"Eur Urol"},{"key":"3046_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Plimack ER, Puzanov I et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19:405\u2013415. https:\/\/doi.org\/10.1016\/S1470-2045(18)30081-0","journal-title":"Lancet Oncol"},{"key":"3046_CR26","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","volume":"66","author":"DYC Heng","year":"2014","unstructured":"Heng DYC, Wells JC, Rini BI et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol 66:704\u2013710. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.034","journal-title":"Eur Urol"},{"key":"3046_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyac099","volume":"52","author":"M Yoshino","year":"2022","unstructured":"Yoshino M, Ishihara H, Nemoto Y et al (2022) Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol 52:1208\u20131214. https:\/\/doi.org\/10.1093\/jjco\/hyac099","journal-title":"Jpn J Clin Oncol"},{"key":"3046_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euros.2023.07.002","volume":"55","author":"EE van de Fransen","year":"2023","unstructured":"van de Fransen EE, van den Brink L, Mansour MA et al (2023) Indications and outcomes for deferred cytoreductive nephrectomy following immune checkpoint inhibitor combination therapy: can systemic therapy be withdrawn in patients with no evidence of disease? Eur Urol Open Sci 55:15\u201322. https:\/\/doi.org\/10.1016\/j.euros.2023.07.002","journal-title":"Eur Urol Open Sci"},{"key":"3046_CR29","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. JCO 33:3541\u20133543. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870","journal-title":"JCO"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03046-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03046-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03046-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:16Z","timestamp":1782407956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03046-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3046"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03046-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8567777\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideaki Miyake received honoraria from Eisai, Merck, MSD, Ono, Pfizer and Takeda. Naoki Matsuyama, Takuto Hara, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Koji Chiba, Akihisa Yao, Jun Teishima have no conflicts of interest that might be relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethical Committee of Kobe University Graduate School of Medicine (approval number: B230087).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was obtained via an opt-out on the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}